| Literature DB >> 24011281 |
Elizabeth E Uhlenhake, Alice C Watson, Peter Aronson.
Abstract
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma. Dermatologic side effects include hand-foot skin reaction, facial and scalp erythema and desquamation, splinter subungual hemorrhages, alopecia, pruritus, xerosis, keratoacanthomas, and squamous cell carcinomas. We report sudden eruption of melanocytic nevi diffusely in a patient receiving sorafenib.Entities:
Mesh：
Substances：
Year: 2013 PMID： 24011281
Source DB: PubMed Journal: Dermatol Online J ISSN： 1087-2108